Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Bulls of Sundial Growers Stock Are Ignoring Reality

By Chris Markoch, InvestorPlace Contributor

The hope that marijuana will become legal in the U.S. is elevating hope that Sundial Growers stock will be an undervalued gem. But traders need to face reality.

You Need More Than Patience to Buy American Airlines

By Chris Markoch, InvestorPlace Contributor

The hope of a Covid-19 vaccine is creating a vaccine rally. But investors should base their decision to buy AAL stock on where it was before the pandemic.

Now Is Not the Time to Load Up on FuelCell Stock

By Chris Markoch, InvestorPlace Contributor

FCEL stock is surging from what a Biden presidency may mean for renewable energy. But hydrogen fuel cells may not be ready to meet the moment.

Workhorse Remains a Speculative Buy With a Capital ‘S’

By Chris Markoch, InvestorPlace Contributor

Workforce competes in an attractive EV niche. But with the status of a major contract likely not decided for six months, WKHS stock remains a speculative buy.

Avoid Boosting the Vaccine Premium on Delta Air Lines Stock

By Chris Markoch, InvestorPlace Contributor

Airline stocks are rising on Covid-19 vaccine hopes. But with a return to normal years away, investors are paying a premium for DAL stock.

Load More